U.S. markets open in 6 hours 7 minutes

Forte Biosciences, Inc. (FBRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2000-0.0200 (-1.64%)
At close: 04:00PM EDT
1.2600 +0.06 (+5.00%)
After hours: 04:31PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.2200
Bid0.0000 x 1000
Ask0.0000 x 1000
Day's Range1.1700 - 1.2900
52 Week Range1.0300 - 43.5700
Avg. Volume170,901
Market Cap18.009M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3570
Earnings DateMay 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for FBRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Forte Biosciences, Inc.
    Analyst Report: Incyte Corp.Founded in 1991 and based in Wilmington, Delaware, Incyte is a drug discovery and development company. The company has several small-molecule compounds in clinical trials, while its primary revenue-generating products include Jakafi, Iclusig, Pemazyre, and Olumiant. Jakafi treats polycythemia vera (PV), a type of blood cancer; myelofibrosis (MF), a rare bone marrow disorder; and steroid-refractory acute graft-versus-host-disease (GVHD), while Iclusig treats leukemia, Pemazyre treats bile duct cancer, and Olumiant treats rheumatoid arthritis. The company also recently launched Tabrecta, for non-small-cell lung cancer, and has several active Phase 2 and 3 programs in oncology.
    Fair Value
    Economic Moat
    18 hours agoArgus Research
View more